Pharmacological rhythm management

PreclinicalSmall molecule

Pharmacological rhythm management is one of 33 small molecule programs targeting Atrial Fibrillation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Calquence

AstraZeneca

Preclinical

1 2

Calan

VVal Adams

Preclinical

4 3

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 4

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 5

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 6

Anticoagulants

Sanofi

Preclinical

2 7

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

1 8

Direct Anticoagulant

Bayer

Preclinical

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

N/ARecruiting

Atrial Fibrillation

NCT06200311

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men

Recruiting·UUniversity Medical Center Groningen·N/A·NCT06200311·604 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pharmacological rhythm management. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pharmacological rhythm management compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pharmacological rhythm management. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Center Groningen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Medical Center Groningen

Pharmacological rhythm management

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Atrial Fibrillation1 trial

References

Drug Info

Quick Facts

Related News